Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance

L. R. Gardell, S. E. Burgess, A. Dogrul, M. H. Ossipov, T. P. Malan, J. Lai, Frank Porreca

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Recent studies indicate that sustained opioid administration produces increased expression of spinal dynorphin, which promotes enhanced sensitivity to non-noxious and noxious stimuli. Such increased 'pain' may manifest behaviorally as a decrease in spinal antinociceptive potency. Here, the possibility of similar mechanisms in the antinociception of spinal cannabinoids was explored. Response thresholds to non-noxious mechanical and noxious thermal stimuli were assessed. Antinociception was determined using the 52°C tail-flick test. Mice received repeated WIN 55,212-2, its inactive enantiomer, WIN 55,212-3 or vehicle (i.th., bid, 5 days). WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced a time-related increased sensitivity to non-noxious and noxious stimuli. WIN 55,212-2, but not WIN 55,212-3 or vehicle, elicited a significant increase in lumbar spinal dynorphin content at treatment day 5. Increased sensitivity to mechanical and thermal stimuli produced by WIN 55,212-2 was reversed to baseline levels by i.th. MK-801 or dynorphin antiserum; control serum had no effect. WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced dose-related antinociception and repeated administration resulted in antinociceptive tolerance. While MK-801 and dynorphin antiserum did not alter acute antinociception produced by WIN 55,212-2, these substances significantly blocked antinociceptive tolerance when given immediately prior to WIN 55,212-2 challenge on day 5. Daily MK-801 pretreatments, prior to WIN 55,212-2 injection, also produced a significant block of antinociceptive tolerance. These data suggest that like opioids, repeated spinal administration of a cannabinoid CB1 agonist elicits abnormal pain, which results in increased expression of spinal dynorphin. Manipulations that block cannabinoid-induced pain also block the behavioral manifestation of cannabinoid tolerance.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalPain
Volume98
Issue number1-2
DOIs
StatePublished - 2002

Fingerprint

Dynorphins
Cannabinoids
Pain
Dizocilpine Maleate
Opioid Analgesics
Win 55212-2
Immune Sera
Hot Temperature
Cannabinoid Receptor Agonists
Tail

Keywords

  • Antinociceptive tolerance
  • Pain
  • Spinal dynorphin

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance. / Gardell, L. R.; Burgess, S. E.; Dogrul, A.; Ossipov, M. H.; Malan, T. P.; Lai, J.; Porreca, Frank.

In: Pain, Vol. 98, No. 1-2, 2002, p. 79-88.

Research output: Contribution to journalArticle

Gardell, L. R. ; Burgess, S. E. ; Dogrul, A. ; Ossipov, M. H. ; Malan, T. P. ; Lai, J. ; Porreca, Frank. / Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance. In: Pain. 2002 ; Vol. 98, No. 1-2. pp. 79-88.
@article{3f282c6f24b6469e8f2678f7507d7b2a,
title = "Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance",
abstract = "Recent studies indicate that sustained opioid administration produces increased expression of spinal dynorphin, which promotes enhanced sensitivity to non-noxious and noxious stimuli. Such increased 'pain' may manifest behaviorally as a decrease in spinal antinociceptive potency. Here, the possibility of similar mechanisms in the antinociception of spinal cannabinoids was explored. Response thresholds to non-noxious mechanical and noxious thermal stimuli were assessed. Antinociception was determined using the 52°C tail-flick test. Mice received repeated WIN 55,212-2, its inactive enantiomer, WIN 55,212-3 or vehicle (i.th., bid, 5 days). WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced a time-related increased sensitivity to non-noxious and noxious stimuli. WIN 55,212-2, but not WIN 55,212-3 or vehicle, elicited a significant increase in lumbar spinal dynorphin content at treatment day 5. Increased sensitivity to mechanical and thermal stimuli produced by WIN 55,212-2 was reversed to baseline levels by i.th. MK-801 or dynorphin antiserum; control serum had no effect. WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced dose-related antinociception and repeated administration resulted in antinociceptive tolerance. While MK-801 and dynorphin antiserum did not alter acute antinociception produced by WIN 55,212-2, these substances significantly blocked antinociceptive tolerance when given immediately prior to WIN 55,212-2 challenge on day 5. Daily MK-801 pretreatments, prior to WIN 55,212-2 injection, also produced a significant block of antinociceptive tolerance. These data suggest that like opioids, repeated spinal administration of a cannabinoid CB1 agonist elicits abnormal pain, which results in increased expression of spinal dynorphin. Manipulations that block cannabinoid-induced pain also block the behavioral manifestation of cannabinoid tolerance.",
keywords = "Antinociceptive tolerance, Pain, Spinal dynorphin",
author = "Gardell, {L. R.} and Burgess, {S. E.} and A. Dogrul and Ossipov, {M. H.} and Malan, {T. P.} and J. Lai and Frank Porreca",
year = "2002",
doi = "10.1016/S0304-3959(01)00475-4",
language = "English (US)",
volume = "98",
pages = "79--88",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance

AU - Gardell, L. R.

AU - Burgess, S. E.

AU - Dogrul, A.

AU - Ossipov, M. H.

AU - Malan, T. P.

AU - Lai, J.

AU - Porreca, Frank

PY - 2002

Y1 - 2002

N2 - Recent studies indicate that sustained opioid administration produces increased expression of spinal dynorphin, which promotes enhanced sensitivity to non-noxious and noxious stimuli. Such increased 'pain' may manifest behaviorally as a decrease in spinal antinociceptive potency. Here, the possibility of similar mechanisms in the antinociception of spinal cannabinoids was explored. Response thresholds to non-noxious mechanical and noxious thermal stimuli were assessed. Antinociception was determined using the 52°C tail-flick test. Mice received repeated WIN 55,212-2, its inactive enantiomer, WIN 55,212-3 or vehicle (i.th., bid, 5 days). WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced a time-related increased sensitivity to non-noxious and noxious stimuli. WIN 55,212-2, but not WIN 55,212-3 or vehicle, elicited a significant increase in lumbar spinal dynorphin content at treatment day 5. Increased sensitivity to mechanical and thermal stimuli produced by WIN 55,212-2 was reversed to baseline levels by i.th. MK-801 or dynorphin antiserum; control serum had no effect. WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced dose-related antinociception and repeated administration resulted in antinociceptive tolerance. While MK-801 and dynorphin antiserum did not alter acute antinociception produced by WIN 55,212-2, these substances significantly blocked antinociceptive tolerance when given immediately prior to WIN 55,212-2 challenge on day 5. Daily MK-801 pretreatments, prior to WIN 55,212-2 injection, also produced a significant block of antinociceptive tolerance. These data suggest that like opioids, repeated spinal administration of a cannabinoid CB1 agonist elicits abnormal pain, which results in increased expression of spinal dynorphin. Manipulations that block cannabinoid-induced pain also block the behavioral manifestation of cannabinoid tolerance.

AB - Recent studies indicate that sustained opioid administration produces increased expression of spinal dynorphin, which promotes enhanced sensitivity to non-noxious and noxious stimuli. Such increased 'pain' may manifest behaviorally as a decrease in spinal antinociceptive potency. Here, the possibility of similar mechanisms in the antinociception of spinal cannabinoids was explored. Response thresholds to non-noxious mechanical and noxious thermal stimuli were assessed. Antinociception was determined using the 52°C tail-flick test. Mice received repeated WIN 55,212-2, its inactive enantiomer, WIN 55,212-3 or vehicle (i.th., bid, 5 days). WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced a time-related increased sensitivity to non-noxious and noxious stimuli. WIN 55,212-2, but not WIN 55,212-3 or vehicle, elicited a significant increase in lumbar spinal dynorphin content at treatment day 5. Increased sensitivity to mechanical and thermal stimuli produced by WIN 55,212-2 was reversed to baseline levels by i.th. MK-801 or dynorphin antiserum; control serum had no effect. WIN 55,212-2, but not WIN 55,212-3 or vehicle, produced dose-related antinociception and repeated administration resulted in antinociceptive tolerance. While MK-801 and dynorphin antiserum did not alter acute antinociception produced by WIN 55,212-2, these substances significantly blocked antinociceptive tolerance when given immediately prior to WIN 55,212-2 challenge on day 5. Daily MK-801 pretreatments, prior to WIN 55,212-2 injection, also produced a significant block of antinociceptive tolerance. These data suggest that like opioids, repeated spinal administration of a cannabinoid CB1 agonist elicits abnormal pain, which results in increased expression of spinal dynorphin. Manipulations that block cannabinoid-induced pain also block the behavioral manifestation of cannabinoid tolerance.

KW - Antinociceptive tolerance

KW - Pain

KW - Spinal dynorphin

UR - http://www.scopus.com/inward/record.url?scp=0036291372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036291372&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(01)00475-4

DO - 10.1016/S0304-3959(01)00475-4

M3 - Article

VL - 98

SP - 79

EP - 88

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-2

ER -